News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

International Wex Technologies (WXI): Open Label Application Filed/Trial Progress


10/19/2005 5:10:40 PM

International Wex Technologies Inc. (the "Company") is pleased to announce that it has received a Screening Acceptance Letter from Health Canada regarding a CTA filing for an open-label extension study of Tectin(TM) in patients with moderate to severe cancer-related pain. Approval for trial commencement is expected by April 9, 2004. This study is a long-term continuation of the Phase IIb/III multicentre, double-blind, placebo-controlled trial. The purpose of the open-label trial is to make Tectin(TM) available to all patients who participate in the Phase IIb/III study, thereby allowing them to benefit from continued treatment while providing the company with data on the long-term safety and efficacy of the product.

Read at CCNMatthews

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES